We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces U.S. FDA Approval of ZEJULA™ (niraparib) for Women with Recurrent Ovarian Cancer
TESARO ANNOUNCES U.S. FDA APPROVAL OF ZEJULA &#8482 (NIRAPARIB) FOR WOMEN WITH RECURRENT OVARIAN CANCER
View HTML
Toggle Summary Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO
NATIONAL HARBOR, Md., March 13, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of secondary endpoint results from the Phase 3 ENGOT-OV16/NOVA trial of niraparib at the 2017 Society for Gynecologic Oncology (SGO)
View HTML
Toggle Summary TESARO Announces Niraparib Data Presentations at the 2017 SGO Annual Meeting on Women's Cancer
WALTHAM, Mass., March 12, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, March 12 to 15, 2017, in National Harbor,
View HTML
Toggle Summary TESARO Announces Fourth-Quarter 2016 Operating Results
Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underway Expanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H 2017 Positive opinion rendered for VARUBY ® by the European Medicine Agency's CHMP; European launch
View HTML
Toggle Summary TESARO Receives Positive CHMP Opinion for VARUBY®
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the Company's marketing
View HTML
Toggle Summary TESARO Announces Participation at Two Investor Conferences
WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Raymond James 38 th Annual Institutional Investors Conference at the JW
View HTML
Toggle Summary Tesaro to Announce Fourth-Quarter 2016 Financial Results on February 28, 2017
WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its fourth-quarter 2016 financial results on Tuesday, February 28, 2017, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15
View HTML
Toggle Summary Tesaro Announces Participation at Two Investor Conferences
WALTHAM, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The 6 th Annual Leerink Partners Global Healthcare Conference at the Lotte
View HTML
Toggle Summary Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer
WALTHAM, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the opening of an expanded access program (EAP) in the United States for the investigational PARP inhibitor, niraparib.
View HTML
Toggle Summary TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA
No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not required Investor conference call and webcast scheduled for tomorrow at 8:30AM ET WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML